Compare Kyndryl Holdings Inc (KD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Zoetis Inc — how do they compare? Kyndryl Holdings Inc trades at $12.03 (market cap $2.69B), while Zoetis Inc trades at $75.15 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 11.9× Kyndryl Holdings Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| KD | ZTS | |
|---|---|---|
Market Cap | $2.69B | $31.95B |
Sector | Technology | Health |
52-Week High | $39.47 | $156.76 |
52-Week Low | $10.59 | $71.91 |
Enterprise Value | $5.03B | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl Holdings (KD) trades at $12.195, up 0.37% on the day, with a neutral technical signal and bullish moving averages. The company reported revenue of $15.06B in 2025, turning profitable with net income of $252M after years of losses. Recent news includes leadership changes, partnership expansions with Microsoft and AWS, and multiple law firm investigations into corporate governance, creating mixed sentiment.
The outlook is cautiously optimistic with a consensus price target of $14.00, implying 15% upside, but risks include ongoing legal probes, volatile earnings history with recent misses, and high debt levels. Improved cash flow and strategic alliances support growth, yet investor confidence remains tempered by governance concerns and margin pressures.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
